Leveraging on GenieBiome's large human metagenomic datasets, we are developing a pipeline of microbiome therapeutics targeting gastrointestinal diseases and conditions that extend beyond the gut, with several candidates for autism spectrum disorder, eczema, obesity/metabolic diseases, and non-alcoholic fatty liver disease in pre-clinical development. The content of our pipeline will change over time as new projects progress from research to development and from development to the market.
Brand names are trademarks either owned by and/or licensed to GenieBiome Limited or associated companies.
We have patented over 20 novel bacteria species that are currently undergoing pre-clinical testing for different diseases.
Targeted Microbiome Supplements:
We have developed new microbiome precision formulas for enhancing immunity separately tailored for adults (G-NiiB-Immunity plus) and children, or entirely personalized to reduce disease-related bacteria markers (G-NiiB Ultra-0301 for Colorectal cancer). GenieBiome also intends to partner with food technology companies to make our novel microbiome delivery system commercially available.
Multi-functional Live Biotherapeutics:
We are developing a novel class of orally administered multifunctional consortia of bacteria with the potential to restore microbiome functionality and resolve specific diseases. We use data from clinical studies of fecal transplant to discover microbes and their metabolites that can be targeted to treat diseases. We are harnessing defined consortia, or collections, of bacteria to modulate microbiome function.
G-NiiB-Ultra-0301 for CRC:
Microbiome precision targeting anti-CRC effects - Utilising deep-sequencing datasets of >600 subjects with CRC and healthy individuals, 3 unique bacteria consortia were identified to be depleted in subjects with CRC. Ultra-0301 was designed to replace these beneficial bacteria species leading to a significant reduction of CRC-related bacteria markers including Fusobacterium nucleatum (Fn).
G-NiiB Immunity infant:
Using metagenomic datasets of infant microbiome profiles and machine-learning analysis, we develop a formula containing 3 immunity-enhancing bacteria consortia, 2 prebiotics, and 2 metabolites approved for use in infants.
Pipeline updated on Aug 3, 2021